LIN-002

N/A

Report date: 2025/01/26 18:01:21

Base Information

Drug NameLIN-002
Drug Alias NameAF-Lx-trastuzumabAuristatin-F-Lx-trastuzumabtrastuzumab-Lx-AFLIN-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancer
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLinXis BV
China Registration ClassN/A

Develop Information

Active CompaniesLinXis BV
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancer
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A